
TG Therapeutics Publishes Five-Year Comparative Analysis of BRIUMVI, Ocrelizumab and Ofatumumab in Relapsing MS
TG Therapeutics Publishes Five-Year Comparative Analysis Showing Favorable Long-Term Outcomes for BRIUMVI in Relapsing Multiple Sclerosis TG Therapeutics, Inc. has announced the publication of results from a five-year matching-adjusted indirect…














